Affimed Announces Promising Interim Results for AFM24-102 Study in EGFR Wild-Type NSCLC and Revenue Growth at ASCO 2024
Mannheim, Germany ’ May 23, 2024’ ’ Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has shared encouraging early efficacy and progression-free survival (PFS) results from its AFM24-102 study targeting advanced epidermal growth factor receptor (EGFR) wild-type (EGFRwt) non-small cell lung cancer (NSCLC). These interim results were announced ahead of the annual meeting of the American Society of Clinical Oncology (ASCO), scheduled to take place in Chicago from May 31 to June 4, 2024.
Affimed’s AFM24-102 study showcases a novel therapeutic approach by combining AFM24, an innate cell engager (ICE), with Roche’s checkpoint inhibitor (CPI), atezolizumab. This combination represents a promising avenue for patients with NSCLC, particularly those who have EGFRwt genetic profiles.
These early efficacy results are highly encouraging for the future of NSCLC treatments, stated Dr. Adi Hoess, CEO of Affimed. The AFM24-atezolizumab combination is demonstrating substantial potential in restoring the innate immune response, which is crucial for combating this aggressive cancer type.
Study Highlights
The AFM24-102 study investigates the synergistic effects of AFM24 and atezolizumab in patients with advanced EGFRwt NSCLC. The initial data indicate:
- ’Positive Early Efficacy’: Patients exhibited favorable response rates, which align with the study’s primary endpoint of assessing the combination’s anti-tumor activity.
- ’Improved Progression-Free Survival (PFS)’: Interim results suggest that the combination treatment significantly delays disease progression compared to standard therapies.
Mechanism of Action
AFM24 is designed to engage natural killer (NK) cells and macrophages, thus enhancing the body’s natural defense mechanisms against tumor cells. When combined with atezolizumab, which works by inhibiting the PD-L1 pathway and further activating T-cells, the treatment aims to create a robust immune response capable of targeting and eliminating cancer cells more effectively than monotherapy.
Revenue Growth
In tandem with the promising clinical developments, Affimed N.V. has reported a revenue increase of 2.45% year-over-year. This financial growth underscores the company’s strong market presence and the potential commercial viability of its innovative therapies. Revenue from corporate clients also demonstrated resilience, maintaining stability during the same period.
Looking Forward
The presentation at ASCO 2024 marks a significant milestone for Affimed and its AFM24-102 study. The company remains committed to advancing the clinical development of its ICE-CPI combination therapy and aims to expand its clinical research to further validate these early findings.
We are proud of the progress to date and are dedicated to continued collaboration with our partners and stakeholders to bring new, effective treatments to patients in need, concluded Dr. Hoess.
Affimed eyes further expansion of its immuno-oncology portfolio while maintaining a strong financial trajectory, thanks to continued revenue growth and strategic investments.
Conclusion
The early data from the AFM24-102 study heralds a potential paradigm shift in treating advanced EGFRwt NSCLC, providing hope for improved patient outcomes and showcasing the innovative prowess of Affimed in the field of immuno-oncology.
Title
Affimed’s AFM24-102 Study Shows Promising Results in EGFR Wild-Type NSCLC and Financial Growth at ASCO 2024’
Comments